Researchers have identified cancer neoantigens and T cells using blood samples, potentially offering a less invasive alternative to traditional tumor biopsies.
Key facts
- •Researchers identified neoantigens and T cells by analyzing ctDNA and immune cells from blood samples.
- •The ctDNA analysis detected 63.25% to 97.4% of the neoantigens identified by standard tissue biopsies in six initial patients.
- •In a broader cohort of 69 patients, ctDNA was detectable in 32 individuals, representing 46.4% of the group.
- •The study found that 14 of 17 patients with colorectal cancer had detectable ctDNA, a rate of 82.4%.
- •T cells isolated from the blood of six out of eight patients showed reactivity to neoantigens identified by the study's methods.
A study published in Cancer Discovery demonstrates that cancer neoantigens and neoantigen-specific T cells can be identified from patient blood samples by analyzing circulating tumor DNA (ctDNA) and immune cells. Led by Alena Gros of the Vall d'Hebron Institute of Oncology, the research suggests this blood-based method could provide a less invasive alternative to traditional surgical biopsies for patients with metastatic solid tumors.
By the numbers
Methodology and Comparison to Biopsy
The research team isolated and sequenced ctDNA from the blood of six patients with various metastatic cancers, including melanoma, breast, head and neck, and colorectal cancer. When compared to conventional tumor tissue analysis, the ctDNA approach identified between 63.25% and 97.4% of the neoantigens found through standard biopsy methods. Additionally, the blood-based analysis detected neoantigens not captured by tissue samples, which researchers suggest may offer a more comprehensive view of tumors in patients with metastatic disease.
Clinical Applicability and Potential Benefits
To evaluate the broader utility of the approach, the researchers analyzed a separate cohort of 69 patients with metastatic solid tumors. They found that ctDNA was detectable in 32 of these patients, or 46.4%. Among a subgroup of 17 patients with colorectal cancer, the detection rate was 82.4%. The study suggests that this method could allow clinicians to identify neoantigens more quickly and reach patients who are unable to undergo invasive surgical procedures due to the location of their tumors or their overall health status.
Future Research and Limitations
While the findings indicate that blood-based identification could complement or replace traditional tissue-based approaches, the authors noted several limitations, including the small size of the patient population and the low prevalence of certain cancer types in the study. Gros stated that further validation in larger patient cohorts is required before the technique can be implemented in clinical settings. Future research may also explore using this approach to monitor how neoantigens and immune responses evolve during the course of treatment.
Advertisement
This article was independently rewritten by ManyPress editorial AI from reporting originally published by Medical Xpress.
